Rich Hey­man's Metacrine grabs a $22M round in search of a su­pe­ri­or NASH drug

A start­up found­ed by biotech A-lis­ters has scored $22 mil­lion in a Se­ries B round to help de­vel­op its NASH drug. The com­pa­ny, called Metacrine, is pur­su­ing a tar­get its founders think can out­per­form the field’s fierce com­pe­ti­tion.

The round was led by new in­vestor New En­ter­prise As­so­ciates, while old in­vestors stayed on board. The mon­ey brings the com­pa­ny’s to­tal haul to $60 mil­lion since its 2015 launch, no doubt buoyed by the rep­u­ta­tion of the peo­ple in­volved.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER